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Abstract 
   Dopamine (DA) is an important neuromodulator of 
the central nervous system; an accurate control of DA levels and the 
resulting interaction with DA receptors is important for a correct brain 
functioning. Several human neurological disorders such as Parkinson’s 
disease and psychiatry disorders are characterized by DArgic 
dysfunctions.  DA D2 receptor (D2R) occupies a privileged position in 
the dopaminergic transmission. D2Rs are widely expressed in the brain; 
importantly, they are expressed presynaptically on dopaminergic 
neurons as well as postsynaptically on neurons targeted by 
dopaminergic neurons. To date it has been impossible to discern pre- 
from post-synaptic D2R-mediated functions. Genetically engineered 
mice, thus, represent important tools to address this question and 
identify D2R functions in vivo. Presynaptically, D2Rs (also named 
autoreceptors) regulate DA synthesis and release from dopaminergic 
neurons; thereby, their activation (i.e. by agonists/antagonists) affects 
mice motor behavior and can be used as readout of autoreceptor 
functions. Importantly, we have recently generated mutants lacking 
D2Rs either from dopaminergic neurons or from striatal medium spiny 
neurons (MSNs). D2 autoreceptor mutants present hyperactivity in a 
novel environment and an increased motor response to cocaine. 
Unexpectedly, we observed that in the absence of these receptors, the 
postsynaptic D2Rs (heteroreceptors) exert an inhibitory control on 
dopaminergic neurons thus affecting the release and the synthesis of 
DA, a function previously thought to be controlled only by D2 
autoreceptors. Conversely, mice lacking D2Rs on the MSNs present a 
strong impairment of movements and an altered response to drugs 
such as cocaine, showing their importance in the regulation of the 
initiation of movement. 
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1. Background 
   DA is the most abundant catecholamine of the 
central nervous system, which is highly conserved among species 
(Cooper and Neckameyer 1999) (Lints and Emmons 1999). DA is 
involved in the modulation of a variety of physiological functions ranging 
from locomotion, motivation, learning and memory to hormone 
secretion, reward and thermoregulation (Blackburn et al. 1992) (Emilien 
et al. 1999) (Missale, et al. 1998). Defects in the dopaminergic 
neurotransmission have been linked to severe pathologies of the central 
nervous system; decrease in the level of DA in the brain leads to a 
neurodegenerative pathology known as Parkinson’s disease, 
characterized by severe impairments such as rigidity, inability to direct 
movements and loss of coordination. This pathology is treated 
administering L-Dopa (a biosynthetic precursor of dopamine) and 
dopaminergic agonists (Olanow et al. 2006). Dopamine is also 
implicated in psychiatric pathologies like schizophrenia (Harrison and 
Weinberger 2005) (Seeman and Van Tol 1994); one of the current 
hypothesis for the disease, based on the beneficial therapeutic effects 
of dopaminergic antagonists, is an over functioning of the system. Also, 
the Attention Deficit Hyperactive Disorder (ADHD) (Cabib et al. 2002) 
(Cummins et al. 2011) as well as Tourette’s syndrome and other 
pathologies are apparently caused by increased dopaminergic 
signaling.The wide variety of human pathologies generated from 
dysfunctions of the dopaminergic system calls for an in depth analysis 
to understand the molecular and cellular mechanisms governing the 
effect of dopamine in the brain. 
 
Dopamine 
   Arvid Carlsson discovered DA in 1957, at the time 
other pharmacologists were skeptical about his findings, and believed 
that DA was merely a metabolite of other transmitters. DA is in fact an 
intermediate step in the biosynthesis of epinephrine and 
norepinephrine. However, a clear demonstration of the function of DA 
as a neuromodulator came from reserpine treatment in rabbits, 
Carlsson and co-workers made the intriguing observation that the 
akinetic effects of reserpine could be reversed by an intravenous 
injection of the DA precursor  3,4-dihydroxyphenylalanine. 
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Carlsson was awarded the Nobel prize for the discovery of DA in the 
year 2000. 
The biosynthesis of DA in dopaminergic neurons starts from the 
aminoacid L-tyrosine, which is hydroxylated by the activity of the 
tyrosine hydroxylase (TH) to 1,3,4-dihydroxyphenylalanine (L-Dopa), 
TH is the rate-limiting enzyme of DA synthesis. L-Dopa is subsequently 
decarboxylated by the Dopa decarboxylase leading to the formation of 
DA (Elsworth and Roth 1997) (Westerink and de Vries 1985) ( Fig. 1). 
DA is then packaged into vesicles, which protects it from enzymatic 
degradation by the monoamine oxidase (MAO). 
Upon nervous stimuli to dopaminergic neurons, vesicles containing DA 
reach the membrane and fuse with it releasing DA in the synaptic cleft; 
this mechanism is Ca2+ dependent (Meir et al. 1999). 
Released DA diffuses also in the extracellular space away from the 
synapse, thus acting on different neurons (Cragg and Rice 2004) 
(Garris, et al. 1994). After signaling, DA is metabolized by two different 
monoamine oxidase  (MAO) that converts DA in 3,4-di-
hydroxyphenylacetic acid and by cathecol-o-methyltransferase (COMT) 
that convert DA in 3-methoxythyramine. 
Depending on the extracellular DA concentration at a given time and in 
a given region, the function of DA is thought to be mainly governed by 
the quantal amount of amine release in response to the pre-synaptic 
depolarization (Rizzoli and Betz 2005) (Sara et al. 2005). Reuptake and 
metabolism are limiting steps of this process. DA released in the 
synaptic cleft is cleared by the DA transporter (DAT) located on the pre-
synaptic terminal. Nevertheless, morphological studies have shown that 
the reuptake mechanism is clearly distant from the point of release 
(Mengual and Pickel 2004) implying an important spill-over of the amine 
released (Rice 2000).It has been also demonstrated that DA released in 
the extracellular space stimulates inhibitor autoreceptors located on 
dopaminergic terminals, thus, inhibiting further release  (Suaud-Chagny  
et al. 1991) (Starke et al. 1989). 
 
 
Tyrosine hydroxylase (TH), a critical enzyme for DA synthesis. 
   TH, as previously mentioned, is the rate-limiting 
enzyme in the cathecolamine’s synthesis; it catalyzes the hydroxylation 
of tyrosine to L-DOPA (Molinoff et al. 1971) (Molinoff and Axelrod 
1971). TH is a tetramer of approximately 240 kDA (Kumer and Vrana 
1996) , which is expressed in the brain, gut and retina, in the 
sympathetic nervous system and the adrenal medulla. This enzyme is 
predominantly found in the cytoplasm (Haycock et al. 1985). DA bound 
TH is inactive, while the DA-free form is active. Phosphorylation of TH 
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by the activity of protein kinase A (PKA) induces the displacement of 
DA, thus increasing the Vmax by sixfold (Haavik et al. 1990). The first 
evidence that TH activity can be regulated by phosphorylation came in 
the seventies (Lovenberg et al. 1975). However, the direct identification 
of the sites of phosphorylation took a decade; it was reported that TH is 
phosphorylated at Ser40, through a cAMP and PKA dependent 
mechanism (Campbell et al. 1986). In vitro also other protein kinases 
have been reported to be able to phosphorylate TH at Ser40 and to 
increase TH activity. Phosphorylation of TH with MAPKK2 or CamKII 
increases TH activity proportionally to the extent of phosphorylation of 
Ser40 (Sutherland et al. 1993). 
 
FIG.1) Schematic representation of DA synthesis. DA is synthesized in 
several brain nuclei of which the predominant are the Substantia Nigra 
compacta and Ventral tegmental area. 
 
DA release 
    The dynamics of the release and uptake of DA into 
and from the synapse as well as from the extracellular space are 
currently under intense investigation. It is now well known that DA is 
also an extrasynaptic messenger  that functions via volume 
transmission, escaping the synaptic cleft to bind to extrasynaptic 
receptors and transporters (Bergstrom et al. 2001). DA is released both 
in a tonic and phasic manner (Schultz 1998) (Wightman and Robinson 
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2002) (Justice  1993), which are best measured by different 
neurochemical techniques. Extensive data indicate that a tonic 
concentration of DA exists in target nuclei that may play an enabling 
role in neurotransmission. In the striatum these tonic concentrations of 
DA are predicted to be 5–20 nmol/L by microdialysis (Justice 1993) and 
differential normal-pulse voltammetry (Suaud-Chagny, Chergui et al. 
1992) and 50–100 nmol/L by theoretical estimations using fast-scan 
cyclic voltammetry (Kawagoe, Garris et al. 1992) and 
pharmacologic studies (Ross 1991). In contrast, extracellular DA 
reaches high concentrations for brief periods (Rebec et al. 1997) 
(Robinson et al. 2001), during phasic release. These transients are 
likely to arise from concerted burst firing of DA neurons (Grace 1991) 
that often occur on presentation of salient sensory input (Overton and 
Clark 1997)(Schultz 1998). Fast-scan cyclic voltammetry  and 
amperometry have been used to measure DA release after an electrical 
stimulation of DA neurons that mimics tonic and phasic firing (Kawagoe 
et al. 1992) (Suaud-Chagny et al. 1995). The amount of DA released is 
frequency-dependent; as the stimulation approaches 
frequencies achieved by burst firing, the DAT is saturated and high 
concentrations are achieved. 
 
Dopaminergic pathways 
 
   DA projections originate in the mesencephalon in 
Nuclei named from A9-A12; from these nuclei four dopaminergic 
pathways have been identified: 1) The Nigrostriatal; 2) the Mesolimbic; 
3) the Mesocortical and 4) the tuberoinfundibular (Fig. 2).  
The nigrostriatal pathway arises from DA-synthesizing neurons of the 
midbrain nucleus, the substantia nigra compacta (SNc) which 
innervates the dorsal striatum (caudate-putamen). The nigrostriatal 
pathway is involved in the control of movement and its degeneration 
causes Parkinson's disease, characterized by tremors, rigidity and 
akinesia (Gerfen 1992) (Lang and Lozano 1998) (Lang and Lozano 
1998). The mesocortical pathway originates from the ventral tegmental 
area (VTA) and innervates different regions of the frontal cortex. This 
pathway appears involved in some aspects of learning and memory (Le 
Moal and Simon 1991). The mesolimbic pathway originates from the 
midbrain VTA and innervates the ventral striatum (nucleus accumbens), 
the olfactory tubercle (OT) and parts of the limbic system. This pathway 
has been implicated in influencing motivated behaviour (Koob and 
Bloom 1988) (Koob 1992). The tuberoinfundibular pathway arises from 
cells of the periventricular and arcuate nuclei of the hypothalamus. 
Projections of this pathway reach the median eminence of the 
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hypothalamus where they release DA into the perivascular spaces of 
the capillary plexus of the hypothalamic–hypophyseal portal system. 
Thus, DA is transported to the anterior pituitary where it acts on the 
lactotrophs to inhibit the release of prolactin. This hormone stimulates 
milk production from mammary glands and stimulates lactotroph 
proliferation by an autocrine mechanism in the pituitary gland (Saiardi et 
al. 1997). 
 
 
 
 
Fig.2) Schematic representation of Dopaminergic pathways. 
1) Nigro-striatal pathway; 2) Mesolimbic-pathway; 3) Mesocortical-
pathway; 4)  tuberoinfundibular-pathway. 
 
DA receptors 
   DA exerts its functions through binding with specific 
membrane receptors (Caron and Lefkowitz 1993). These receptors 
belong to the family of seven transmembrane domain G-protein coupled 
receptors (GPCR). The first evidence for the existence of DA receptors 
were biochemical and pharmacological and obtained in the seventies 
(Caron et al. 1978) (Kebabian 1978). With the increasing advancement 
of molecular cloning techniques and a great biochemical support, the 
first GPCR cloned was the -adrenergic in the eighties; this cloning 
opened the way to the molecular identification of most GPCR using low 
stringency cloning strategies and PCR. This way five different genes 
encoding for five different dopaminergic receptors have been cloned, 
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and named: D1, D2, D3, D4, D5. Interestingly, the cloning techniques 
identified more receptors than expected based on pharmacological 
evidence, which identified only two classes the D1 and D2. However, 
when these cloned receptors were expressed in cells and their 
pharmacology studies it was possible to group them into 2 different 
families: the D1-like and D2-like family. The D1 and D5 receptors 
belong to the D1-like family and D2, D3, D4 belong to the D2-like family. 
Importantly, members of the same family share not only 
pharmacological but also structural and biochemical properties (Table 
1). The D1-like receptor’s family interacts with the stimulatory G-
proteins (Gs) and activates the adenylyl cyclase; while the D2-like 
family is characterized to inhibit this same effector (Gingrich and Caron 
1993) (Missale et al. 1998) (Jackson and Westlind-Danielsson 1994). 
DA receptors share the characteristics of typical 7 transmembrane 
domains receptor connected by three intracellular and three 
extracellular loops with an extracellular N-terminus and an intracellular 
C-terminus. 
 
 
 
Table 1) Pharmacological table of dopaminergic receptors: agonists 
and antagonists. 
 
 
 
 
  
10 
 
The D1-like family 
 
 
The D1 Receptor 
 
   The D1 receptor was cloned for the first time in 
1990 (Monsma et. al. 1990). This receptor is characterized by a short 
third cytoplasmatic loop and a long C-terminus. These are typical 
characteristics of receptors linked to Gs and activator of the adenylyl 
cyclase, such as the -adrenergic receptor (Dohlman et al. 1991) . D1 
mRNA has been found in the striatum, the nucleus accumbens and the 
olfactory tubercle. In addition, D1 receptors have been detected in the 
limbic system, hypothalamus and thalamus (Missale et al. 1998). 
Pharmacological, biochemical and behavioral studies, of animals 
knockout for this receptor, have been shown the importance of D1-
mediated signaling in locomotion (Xu et al. 1994),learning, and 
responses to drugs of abuse (Caine et al. 2000) (Tzschentke and 
Schmidt 1998) (Smith et al. 1998) among several other deficits. D1 
agonist overstimulation of this receptor has also been linked to 
stereotype-like behavior in rats and mice models (Makihara, et al. 2004) 
(Wilkinson and Nichol 2000). 
 
 
The D5 receptor 
 
   The D5 receptor gene has a more restricted pattern 
of expression when compared to the D1 receptor; its expression has 
been detected in the hippocampus, lateral mammillary nucleus, and in 
the parafascicular nucleus of the thalamus (Jackson and Westlind-
Danielsson 1994). This receptor is composed of 475 amino acids and it 
is not pharmacologically different from the D1 receptor. The only 
difference is in the affinity of the receptor for DA, D5 receptors have 
indeed 10 times higher affinity for DA than the D1 receptor (Table 1) 
(Grandy et al. 1991) (Missale et al. 1998). Low levels of D5 expression 
have been reported in the prefrontal cortex, hyppocampus, 
hypothalamus, in the olfactory bulbs, in the Nucleus Accumbens (NAcc) 
and the Caudate putamen (Cpu) (particularly in striatal interneurons) 
(Sealfon and Olanow 2000). 
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D2-like family 
 
The D2 receptor 
 
   The D2 receptor has been the first member of D2-
like family to be cloned. The cDNA encoded for a protein of 415 amino 
acids (Bunzow et al. 1988). 
As compared to the D1 receptor, the D2 receptor contains: I) 3 potential 
consensus sites for glycosylation in the N-terminus; II) a smaller C-
terminus; III) a larger third intra-cytoplasmatic loop (Bunzow et al. 1988). 
These chacteristics are typical of many receptors known to inhibit the 
adenylyl cyclase activity (Dohlmanr et al. 1991). 
In 1989 a new form of D2 receptor of 444 amino acids (aa) was 
discovered; this other isoform was then recognized to originate by 
alternative splicing of the Drd2 gene (Dal Toso et al. 1989) (Giros, et al. 
1989) (Montmayeur, et al. 1991) (Fig.3) 
This mechanism inserts exon 6, a very small exon of only 87 
nucleotides, in the pre-mRNA. This insertion leads to the presence of 
additional 29 aa in the third intracytoplasmatic loop of the longest 
isoform of the D2 receptor: D2L. The other isoform is identical to D2L 
but does not contain the insert and therefore is shorter; from which the 
name D2S. D2L has higher affinity than D2S for the G-protein Galphai2 
(Montmayeur et al. 1991) (De Mei, et al. 2009) which has led to the 
hypothesis that the two isoforms by differential coupling might have 
different functions in vivo. 
The ratios of D2L/D2S expression favors D2L in all neurons (80/20), 
with the only exception of the Substantia nigra compacta (SNc) and 
ventral tegmental area (VTA) where the ratio is 50/50. Thus suggesting 
a possible DA autoreceptor role for D2S (Montmayeur et al. 1991). 
(Usiello et al. 2000) 
How the splicing of the Drd2 is regulated starts to be elucidated recently 
it has been identified a heterogeneous nuclear ribonucleoprotein M 
(hnRNP M) as a key molecule controlling D2R splicing. It has been 
shown that binding of hnRNP M to exon 6 inhibited the inclusion of this 
exon in the mRNA (Park et al. 2011). In the past, a role for steroids in 
regulating the splicing events was reported (Guivarc'h et al. 1998). 
The observation that D2L and D2S have similar pharmacological 
characteristics and localization led to hypothesize that they might have 
redundant functions. However, as previously mentioned, biochemical 
and cellular studies identified slight differences among these isoforms. 
An important evidence on the different role of the two isoforms came 
from the analysis of knockout mice for the D2L isoform (Usiello, et al. 
2000). Indeed, it showed that absence of D2L removes the postsynaptic 
response to the typical antagonist haloperidol while preserving D2-
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mediated autoreceptor functions (Usiello, et al. 2000) (Wang, Xu et al. 
2000). 
 
 
FiG. 3) Schematic representation of the 2 isoforms of D2R. 
On the top the D2L isoform; on the bottom the D2S isoform. 
 
 
Thus supporting that D2L and D2S are not redundant but serve specific 
roles in vivo. 
D2 receptors are higly expressed in the striatal regions and basal 
ganglia; they are also expressed although to minor extent in the 
hyppocampus and amygdala (Mansour et al. 1990) (Mengod et al. 
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1992). In the cerebral cortex DA D2 receptors are expressed in the 
anterior cingulate cortex (Mansour  et al.1990; Mengod et al. 1992). 
In the midbrain D2 receptors are highly expressed in the dopaminergic 
neurons in the VTA and SNc (Mansour, et al. 1990). 
D2 receptors are also expressed in the anterior and intermedial lobes of 
the pituitary gland (Mansour. et al. 1990) (Mengod et al. 1992). D2 
receptors are expressed in the retina (DA is the most predominant 
cathecolamines in the vertebrates retina (Witkovsky 2004), lungs, 
intestine and vascolar systems. D2 signaling might also be involved in 
the regulation of circadian rhythms (Doi et al. 2006) (Hood et al. 2010). 
 
 
The D3 receptor 
 
   The second DA receptor cloned of the D2-like 
family was the D3 (Sokoloff et al. 1990). D3 has higher affinity than D2 
for DA and it is glycosilated at the N-terminal as the D2 receptor  
(Sokoloff et al. 2006). 
The more interesting feature is that the Drd3 gene also undergoes to 
splicing, however in this case the products are truncated receptors. The 
function of the different splicing variants has not been studied in depth.  
D3 receptor has a overall 52% homology with the D2 receptor; the 
transmembrane regions have however a 75 % homology. This higher 
structural homology results in the absence of compounds that can 
pharmacologically discriminate D3 from D2; indeed, to date only few 
antagonists have been described to be slightly selective for D3, 
relatively to D2 receptor (Gilbert et al. 2005) (Xi et al. 2006). Agonists 
have either equal or greater affinity for the D3 receptor (Sokoloff and 
Schwartz 1995). 
DA D3 receptors are slightly expressed in the ventral striatum and very 
strongly in the island of Calleja; D3 receptors are also expressed 
presynaptically in dopaminergic neurons of the VTA and SNc (Diaz, et 
al. 2000) (Hall et al. 1996). 
 
 
The D4 receptor 
 
   The last cloned member of the D2-like family is the 
D4 receptor (Van Tol, et al. 1991). 
The receptor is a protein of 387 amino acids. D4 receptor has 41 % 
homology with D2 receptor and 39% with D3, and about 56% for both 
D2 and D3 receptors within the membrane–spanning domains. There is 
one potential site for N-linked glycosilation in the N-terminus and one 
consensus cAMP-dependent phosphorylation site in the third 
cytoplasmatic loop (Van Tol et al. 1991). Ligand binding studies reveal 
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a pharmacological profile similar to those of D2 and D3 receptors. The 
D4 receptor display similar or lower affinity for both dopaminergic 
agonist and antagonist compared to the D2 receptor (Van Tol, et al. 
1991). Recently the generation of D4 specific ligands has been 
reported, thus opening the possibility for a specific pharmacological 
characterization of this receptor. 
The D4 receptor is weakly expressed in different areas of the brain such 
as the cerebral cortex, amygdala, hypothalamus, and pituitary gland; it 
is also abundant in the retina (Defagot et al. 2000) (Lidow et al. 1998). 
Several variants of D4 receptors have been found, particularly in the 
exon coding for the third cytoplasmatic loop (Van Tol et al. 1992). 
Clinical studies have reported a correlation between polymorphisms of 
this gene and the ADHD in the human population (Faraone, et al. 
2001)); in addition, an increasing number of D4 receptors have been 
found in schizophrenic patients, suggesting the possible involvement of 
this receptor in human psychoses (Ariano, et al. 1997) (Mrzljak, et al. 
1996). 
 
 
The dopamine trasporter (DAT) 
 
    Dopaminergic neurons express the DAT; this 
protein is involved in the reuptake of DA from the synapse. DAT is a 
member of the Na+/Cl- transporter family, the protein contains 12 
transmembrane domains (Giros and Caron 1993) (Amara and Kuhar 
1993). 
DAT mediates the recapture of released DA and, together with the D2 
autoreceptor, is a key regulator of dopaminergic signaling, by regulating 
extracellular DA levels. DAT is expressed only in the cells that 
synthesize DA (Torres, et al. 2003). It is a crucial target for different 
psycho-active drug such as cocaine (Giros, et al. 1996). 
DAT has been shown to interact directly with the D2 receptor, the N- 
terminal of DAT interacts with the third cytoplasmatic domain of the 
D2R (Bertolino, et al. 2009). The interaction between DAT and D2R 
helps the recruitment of DAT reinforcing the DA reuptake. (Lee et al. 
2007). 
 
 
Basal ganglia 
 
    The basal ganglia are involved in the performance 
and selection of the action, they are the center of interaction of different 
brain areas, in which there is a cohesive functional unit of different 
information such as voluntary motor control, emotional functions and 
habits behavior (Groenewegen 2003) (Gurney et al. 2004). The basal 
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ganglia network is composed of five large subcortical nuclei: the 
caudate nucleus, the putamen, the globus pallidus, the subthalamic 
nucleus and the substantia nigra (Groenewegen 2003). These circuits 
have 3 different functional activity: motor activity, cognition and 
motivational behavior (Kreitzer and Malenka 2008) (Nambu 2008). 
Inside the basal ganglia functional circuit, DA has the crucial role to 
modulate motor functions (Heien and Wightman 2006) (Schultz 2007) 
through the activation of two pathways contained in this circuit, the 
direct and indirect pathways. The direct pathway is formed by the 
striatal projections to the internal segment of the globus pallidus and 
substantia nigra pars reticulata, which then project to the thalamus. The 
indirect pathway projects from the striatum to the external segment of 
the globus pallidus, which then projects to the subthalamic nucleus and 
from this nucleus to the substantia nigra reticulata. 
In the classical model of the direct and indirect pathway D1R- and D2R- 
mediated effect are largely segregated (Gerfen 2000); with D1R 
regulating the indirect pathway and D2R the direct pathway (Gerfen 
2000). 
 
 
Striatum 
 
    Anatomically the striatum is a structure of the 
forebrain. It is composed by caudate, putamen, ventral striatum and 
globus pallidum. 
Anatomical studies showed that the striatum is the target of the 
afferences from the cerebral cortex, intralaminar thalamic nuclei and the 
DAergic neurons. 
Striatal neurons have been characterized anatomically and functionally 
(Kawaguchi, et al. 1995) (Wilson 1993) and can be divided into two 
different classes: the medium spiny neurons (MSNs), and the 
interneurons. The MSNs represent the majority of striatal cells (~95%); 
MSNs can be divided into striatonigral neurons (direct pathway) and 
striatopallidal neurons (indirect pathway) (Gerfen 2000) (Gether 2000) 
(Smith et al. 1998). MSNs are gabaergic neurons, but they are also 
known to synthetize substance P, enkephalin (ENK), dynorphin (dyn) 
and neurotensin (NT). The interneurons represent only 5% of the 
striatal neurons, they can be divided in 4 classes: the giant colinergic 
interneurons, parvalbumin containing gabaergic interneurons, calretinin 
containing gabaergic interneurons and somatostatin containing 
interneurons (Kawaguchi et al. 1995). Interneurons receive 
glutamatergic afferences from cortical area and thalamus and they 
innervate MSNs or others interneurons (Tepper and Bolam 2004). 
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D1R and D2R localization 
 
    D1R and D2R are the most abundant DA receptors 
in the brain, particularly in the basal ganglia. Both receptors are 
segregated in the MSNs of the striatopallidal and striatonigral pathways 
(Surmeier et al. 2007); however, single cells PCR analyses have shown 
that D1R and D2R might colocalize in the 20% of striatal neurons 
(Surmeier and Kitai 1994) (Surmeier et al. 1996). This number was 
further increased in a report using immunocytochemical and confocal 
techniques, which reported, surprisingly, that all striatal cells express 
both D1R and D2R (Aizman et al. 2000). However, recent studies using 
transgenic mice expressing D1R and D2R proteins tagged with 
fluorescent markers contradicted these findings and showed that just 
5% of MSNs express both receptors (Matamales et al. 2009). These 
studies have also shown that cholinergic interneurons express only 
D2R. However between the two receptors, in the basal ganglia circuit 
the major difference for what concern their localization is that D1R are 
only expressed by MSNs while D2 receptors are expressed MSNs, 
interneurons as well as by dopaminergic neurons of the SNc and VTA 
(Matamales et al. 2009), having the important role of autoreceptor.  
 
 
Pre- and postsynaptic functions of D2R 
 
    As explained in previous paragraphs, D2R is 
expressed in all dopaminergic neurons as well as in MSNs and 
interneurons. Studies performed using D2R KO mice have shown that 
D2R is the only receptor of the dopaminergic system to function as 
autoreceptor, regulating the synthesis and release of DA (Dickinson et 
al. 1999) (Rouge-Pont et al. 2002) (Benoit-Marand et al. 2001). Indeed, 
results obtained using complementary microdialysis and voltammetry 
analyses show that the autoreceptor function regulating DA release is 
totally abolished in the absence of D2R in D2R KO mice (Rouge-Pont et 
al. 2002). D2R has also been shown to have a key role in the auto-
inhibition of DA release in response to drugs of abuse; this can be very 
likely related to the fact that DAT activity might be affected in the 
absence of D2R (Bertolino et al. 2009). D2R has been reported to 
regulate the trafficking of DAT at the plasma membrane through 
activation of the MAPK pathway (Bolan et al. 2007) (Lee et al. 2007). 
Interestingly, in mice lacking D2L (D2L KO), which still express D2S, 
the D2R mediated autoreceptor function is still present. This suggested 
a specific autoreceptor role for the D2S isoform in vivo (Lee et al. 2007) 
(Usiello et al. 2000).  
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Dopaminergic neurons originating in the midbrain bring information to 
the striatum that regulates motor activity and reward; in parallel 
glutamatergic afferences from cortical areas converge to the striatum, 
where DA signaling balances the arrival of this information (Wise 2005). 
At the same time, DA through D2R also controls the activity of the 
interneurons, whose role is important for a correct regulation of striatal 
physiological functions (Wang et al. 2006) (Surmeier et al. 2007). 
Postsynaptically, D2 receptor is needed for a correct regulation of the 
different stimuli arising from different area of the brain. D2R on the 
MSNs working as heteroreceptor modulates the release of other 
neurotransmitters in striatal and cortical cells; therefore this receptor 
influences not only DA release but also that of neurotransmitters 
produced by neurons target of DA afferents. 
Pre-synaptic mechanisms mediated by D2R have been implicated in 
the GABA and glutamate release (Centonze et al. 2004) (Centonze et 
al. 2002) from striatal and cortical neurons. Altogether, these 
experimental evidence make D2R a key regulator of dopaminergic 
transmission not only at the level of dopaminergic neurons but also in 
heterologous systems.  
 
 
Signal transduction 
 
   The best characterized intracellular effect of DA is 
on the cAMP pathway (Tan et al. 2003) (Nishi et al. 1997). This pathway 
is activated by the D1-like receptors and inhibited by the D2-like 
receptors. In MSNs, elevation of cAMP level leads to the activation of 
the Protein Kinase A (PKA) (Nishi et al. 1997) and consequently to the 
phosphorylation of a large series of cellular targets and importantly of 
the DA- and cAMP-regulated phosphoprotein of 32 kDa (DARPP-32) 
(Bateup et al. 2008). Blockade of D2R stimulates the PKA-
dependent phosphorylation of DARPP-32. This effect is most probably 
mediated via suppression of the inhibition exerted by D2R on adenylyl 
cyclase.  Phosphorylation catalyzed by PKA on Thr34 converts DARPP-
32 into a potent inhibitor of Protein Phosphatase 1 (PP-1), thereby 
amplifying the responses produced by activation of the 
cAMP/PKA pathway. Importantly, blockade of D2R-mediated signaling 
produces a motor depressant effect, which is attenuated in DARPP-32 
null-mice (Fienberg et al. 1998). Activation of D1Rs increases 
Thr34 phosphorylation via Golf-mediated stimulation (Herve et al. 2001).  
Conversely, activation of D2Rs decreases DARPP-
32 phosphorylation at Thr34 via Gi-mediated inhibition of cAMP 
production (Nishi et al. 1997). 
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In addition, D2R agonists stimulate protein phosphatase-2B activity, 
thereby increasing dephosphorylation of DARPP-32 at Thr34 (Nishi et 
al. 1997). 
D2 like receptors have also an activity cAMP independent in which AKT 
is a crucial protein. When DA binds D2R there is the formation of a 
complex of three proteins: beta-arrestin, AKT and the phosphatase 
PP2a (Beaulieu et al. 2005). Akt is inactivated through 
dephosphorylation of thr-308 by PP2A (Beaulieu et al. 2005). AKT 
inactivation leads to activation of GSK 3 (Glycogen synthetase 3) 
consequently in this way some dopaminergic behaviors are mediated 
by signaling pathways different from that of the cAMP (Beaulieu et al. 
2007). Importantly, in schizophrenic patients, in which D2R antagonists 
are the drugs of choice, Akt expression is down-regulated and 
conseguently GSK 3 phosporylation is decreased (Emamian et al. 
2004). Thus, the cAMP independent induction of the AKT pathway by 
DA through D2Rs might have strong repercussions on human health. 
 
 
Gene Targeting 
 
Generation of  ko mice 
 
   The embryonic stem cells were isolated for the first 
time in the eighties (Evans and Kaufman 1981). These cells are 
totipotent, thus they have the ability to differentiate in all possible 
lineages during the development of the animal, including the germ line. 
These cells can be grown in vitro and they can be manipulated without 
altering their capacity to be totipotent. Recombinant DNA can be 
transfected in these cells, which then integrate the genome through the 
process of homologous recombination. In this way it is possible to 
introduce mutation in the gene of interest or generate knockin/knockout 
mice. Indeed, once isolated the desired clone, these cells can be 
implanted in mouse embryos, where they have the ability to colonize 
the embryos giving rise to chimeras and through subsequent mating to 
recombinant mouse lines (Capecchi 1989). The desired cells are 
obtained by selection on known resistance introduced in the cells by the 
recombinant vector. Embryonic stem cells for the generation of mutant 
mice originate from the 129/sv strain which after manipulation will be 
implanted into a pseudo-pregnant female of the C57BL/6j strain. The 
continuous backcrossing on a specific background allows for the 
establishment of animal lines homozygous for the modified gene (a null 
mutant) (Thomas and Capecchi 1987). 
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Generation of site-specific knockout mice 
 
    In vivo analysis of gene function is often based on 
the production of animal models with specific genetic modification. This 
approach has been applied to several areas in biological research. To 
highlight the importance of the same gene products in different areas, 
the Cre-loxP system has been one of the best tools used in the last 20 
years. The Cre recombinase is a 38 kDA protein encoded by 
bacteriophage P1 and it can catalyze the specific recombination 
between DNA specific sites called loxP sites (Sauer 1987; Sauer et al. 
1987). When two loxP sites are introduced in the same orientation into 
a genomic locus, expression of the CRE recombinase results in the 
deletion of the loxP flanked DNA sequence. Introduction of two loxP 
sites in to the genome flanking an essential part of a target gene without 
affecting its function and subsequent Cre-mediated deletion will lead to 
the inactivation of the gene of interest. A specific transgenic Cre mouse 
expressing the recombinase under the control of a region specific 
promoter will allow the deletion of the gene in the region of interest (Fig 
4). 
 
 
 
 
 
FIG.4) Schematic representation of the Cre-lox system. 
The exon 2 of the protein is flanked by two LoxP sites. Mating this 
mouse with an animal expressing the Cre-recombinase leads to the 
excision of the exon. 
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2. Aims of this study 
 
    Understanding how DA regulates important 
physiological functions is a arduous subject due to the existence of five 
different DA receptors sharing the same ligand and transduction 
pathways and as in the case of the D2 receptors have two isoforms with 
similar pharmacology(Usiello et al. 2000; Wang et al. 2000).Therefore, 
while it is possible to discriminate pharmacologically between the two 
different sub-families of DA receptors, it is impossible to discriminate 
pharmacologically between members of the same family. The 
generation of specific KO mice highlights the value of cell-specific 
conditional mutant mouse models to determine the importance of the 
same gene product in different neurons. 
During my thesis, I have attempted to elucidate the role of the 
presynaptic D2R (autoreceptor) and postsynaptic D2R (heteroreceptor) 
in the physiological control of DA release and their specific involvement 
in presynaptic (dopaminergic neurons) and post-synaptic (MSNs) 
functions. 
My work has been concentrated on the analysis of two animal models 
generated in the laboratory before my arrival. These animals are D2R 
site-specific mutants in which the specific ablation of either the 
presynaptic D2R (autoreceptor) or the postsynaptic D2R 
(heteroreceptor) has been achieved. The presentation of my results is 
articulated in two main parts. In the first part, I will present the 
pharmacological and behavioral analyses performed in each mutant. In 
the second part, I will present the consequences of the ablation of D2R 
at pre- and postsynaptic sites on DA synthesis, release and DA-
dependent functions. 
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3. Materials and Methods 
Animals 
   Animals were housed under standard conditions 
(12 h light/dark cycles) with food and water ad libitum. All experiments 
were in accordance to the Institutional Animal Care and Use 
Committees (IACUC). 
Drugs 
    (-)Quinpirole Hydrochloride, Haloperidol and 
Cocaine Hydrochloride were from SIGMA, Baclofen from Tocris. All 
drugs were dissolved directly in 0.9% NaCl; haloperidol was dissolved 
as previously described (Usiello et al. 2000). 
Generation of mice. 
    To generate D2R floxed alleles, a LoxP site was 
first inserted 5’ of the 900 bp NcoI genomic fragment of the D2R gene 
containing exon 2; to allow selection of the recombinant ES cells, a 
neomycin cassette (pGKneo), flanked by LoxP sites, was inserted at the 
3’ end of the NcoI genomic fragment (Fig. 5). This generated the LoxP-
Exon2-LoxP-pGKneo-LoxP construct, which contained an additional 
HindIII site allowing discrimination between the WT and floxed alleles 
(Fig.5). The endogenous NcoI fragment of the D2R gene was then 
replaced with this construct in the KpnI-SalI genomic fragment of 6.5 Kb 
(Fig.5). The engineered KpnI-SalI fragment was then used to 
electroporate ES cells (129/S6 H1). Chimeras obtained from the 
injection of positive clones successfully transmitted the mutation to the 
progeny and homozygous D2Rfloxflox mice were obtained. D2Rfloxflox mice 
were then mated with En1Cre mice to generate D2Rfloxflox/En1Cre/+ 
animals and D1Cre mice to generate D2Rfloxflox/D1Cre/+ mice. Mutant and 
control mice used in this study are in the same genetic background 
(87.5% C57Bl6 x 12.5% 129 SV). During the establishment of the two 
mutants lines, we selected by Southern analyses only mice containing 
the excision of the neomycine cassette. 
Genotyping. 
   Southern blot analyses were performed (Baik et al. 
1995) on genomic DNA from tail biopsies of D2Rfloxflox , D2Rfloxflox/En1Cre/+ 
and D2Rfloxflox/D1Cre/+mice. Genomic Hind III digests revealed fragments 
of 2.5 Kb in D2Rfloxflox and 2 Kb in D2Rfloxflox/En1Cre/+ and D2Rfloxflox/D1Cre/  
mice after hybridization to the 32P-labelled NcoI-SalI mouse D2R 
genomic fragment. A 5.5 Kb fragment corresponding to the CRE 
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recombinase was obtained in both mutant lines using a 1.12 Kb 32P-
labelled probe, containing the CRE coding region. 
 
In situ hybridization. 
   Brains were rapidly dissected, snap frozen in 
isopentane-dry ice and stored at - 80°C. Coronal cryostat sections (10 
μm) were hybridized with 35S-CTP-labelled D2R exon 2-specific probe 
as previously described (Baik et al. 1995) (Welter et al. 2007). Double in 
situ hybridizations of sections from D2Rfloxflox and D2Rfloxflox/D1Cre/+ were 
performed using a 35S-labeled D2R-specific exon 2 probe together with 
the digoxigenin (DIG)-labeled choline acetyl transferase (ChAT) or 
glutamic acid decarboxylase 1 (Gad1) probes. Radioactive probes were 
prepared as previously described (Baik et al. 1995) and cold probes as 
(Clark et al. 2001).Pictures were taken at 20x with a bright microscope 
(Leica). 
 
D2R and D1R ligand-binding assays. 
   D2R and D1R ligand-binding assays were carried 
out on striatal membranes using [³H]-Spiperone for D2R (specific 
activity 91 Ci mmolˉ¹;Amersham) and [³H]-SCH23390 (specific activity 
specific activity 85 Ci mmolˉ¹;Amersham) for D1R. Binding data were 
analyzed with GraphPad Prism 4.0 program (GraphPad software). 
Binding assays were performed as previously described (Baik et al. 
1995). 
Behavioral analyses. 
   Behavioral experiments were performed using male 
mice (>8 week old). 4 days before experiments mice were moved to 
soundproof behavioral rooms. The open field was a white square box 
(30 x 30 cm; 70 lux); the home cage was a transparent plastic box (20 x 
30 cm). Activity was followed by a video-tracking system (Viewpoint, 
Lyon, France) for 1 hour. An observer blind to mouse genotype scored 
rearing activity during the first 5 min of each test. Quinpirole (i.p.) effect 
was observed in animals not habituated to the testing cage (20 x 30 cm) 
or (30x30 cm) and analyzed for 30 minutes. Cocaine (i.p.) was 
administered after habituation to a new home cage (1 hr) and activity 
recorded for 30 min. Catalepsy by haloperidol (i.p.) was evaluated by 
the bar test (Usiello et al. 2000). Time spent in a cataleptic position was 
scored 3 h after treatment; cutoff was given at 120 seconds.  
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Western blots. 
   Animals treated with saline, quinpirole (0.2 mg/kg; 
i.p.), were killed 30 min after the administration of the compound.  
Heads were immediately immersed in liquid nitrogen for 6 s. Brains 
were frozen, punched in the region of interest and processed as 
previously described (Svenningsson et al. 2000) to preserve 
phosphorylations. Protein determination was made by BCA 
(bicinchoninic acid). Equal amounts of proteins (30 µg) were loaded 
onto 10% SDS/PAGE and transferred to PVDF membranes (BIO-RAD). 
Western analyses were performed using antibodies directed against 
phosphor-Ser40-TH (1:1500;Millipore), total TH (1:3000;Millipore), α-
tubulin (1:5000;Sigma); Goat anti-rabbit secondary antibodies 
(1:5000;Millipore) were used and blots revealed with ECL Plus. 
Quantifications were performed using NIH Image (version 1.42q) 
software. 
 
Amperometry and cyclic voltammetry. 
   Adult male D2Rfloxflox and D2Rfloxflox/En1Cre/+ or 
D2Rfloxflox/D1Cre/+ were analyzed the same day. Slices were cut at 250 m 
and allowed to recover at room temperature for 1.5 hours. Recording 
temperature was ~30 °C, and carbon fiber electrodes were placed close 
to corpus callosum (laterodorsal to dorsal section). For amperometry 
(AMP), a constant voltage of +500 mV was used and traces were 
digitally filtered using a Gaussian filter (250 Hz cutoff frequency). For 
cyclic voltammetry (CV), electrodes were calibrated before and after 
each experiment to estimate DA concentration. Each protocol was 
performed independently, except the paired pulse experiments 
performed in CV. Eight prepulses were applied to achieve constant DA 
release. Single-pulse DA levels and decay parameters were measured 
using the eighth prepulse. Paired-pulse experiments were performed 
using AMP (0.5 and 1 s) and CV (5–60 s). Trains of five or ten pulses at 
20 Hz were analyzed by CV. Quinpirole was applied for 10 minutes, 
then removed and washed for additional 10 minutes.  
Cell-attached electrophysiological recordings from adult mouse 
brain slices. 
   Horizontal midbrain mouse slices (200 μm) 
preparation, recovery and external solutions were made as described 
(Kapfhamer, Berger et al. 2010). Cells were visualized with an upright 
microscope using infrared differential interference contrast (IR-DIC) 
illumination and cell-attached voltage clamp recordings were made with 
a Multiclamp 700A amplifier (Axon Instruments). Electrodes (2–4 MΩ) 
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contained in mM: 117 cesium methansulfonic acid, 20 HEPES, 0.4 
EGTA, 2.8 NaCl, 5 TEA-Cl, 2.5 MgATP, 0.25 MgGTP (pH 7.2–7.4), 
275–285 mOsm. Baclofen (2 μM) and Quinpirole (2 μM) were applied 
by bath superfusion. 
HPLC analysis. 
Tissues were homogenized by sonication in 30 volumes (w/v) of ice-
cold 100 mM HClO4. The homogenates were centrifuged for 20 min at 
15,000 g, 4 C. The supernatants were recovered and passed through 
0.2 µm filters and monoamines and metabolites quantified in the filtrates 
by HPLC-EC. The HPLC system consisted of a BASi (West Lafayette, 
IN) LC-4C detector coupled to a BASi LCEC radial flow cell. Flow was 
provided by a Shimadzu (Columbia, MD) LC-20AD solvent delivery 
module, preceded by an online degasser series 1100 from Agilent 
(Santa Clara, CA). The chromatograms were analyzed using 
PowerChrom software (eDAQ, Colorado Springs, CO). Monoamines in 
10 µl tissue filtrate were separated on a 1 x 100 mm UniJet microbore 5 
µm C-8 column. The mobile phase consisted of 24 mM Na2HPO4, 0.3 
mM sodium octyl sulfate, 27.4 mM citric acid, 107 µM EDTA and 11 % 
(v/v/) MeOH, pH adjusted to pH = 4.5 with NaOH. The flow was set at 
100 µl/min and the potential was set at + 750 mV relative to an Ag/Cl 
reference electrode. Elution times were as follows (in min): DOPAC = 
2.6; Dopamine = 5.1; HVA = 6.4;  
 
Statistical analysis. 
   All values are given as mean ± S.E.M. Analysis of 
variance (ANOVA) was used to determine group effects and 
interactions followed by the appropriate Post-hoc comparison or 
Student’s t-test (P < 0.05 was considered statistically significant). 
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4. Results and Discussion 
 
 
Analysis of the D2R site-specific  knockout mice 
 
   To evaluate the pre- and post-synaptic functions of 
the D2R receptor, site-specific mutant have been generated. To 
generate them, the exon 2 of the D2R gene was flanked by loxP sites 
and D2Rfloxflox mice were generated, these mice are indistinguishable 
from their control wild-type (WT) mice (Fig.5). 
 
 
 
 
 
 
Fig 5) Strategy to generate D2Rfloxflox  mice. 
          
… 
represents the probe used for genotyping.
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Presynaptic D2 autoreceptor mutants 
    
   To study the presynaptic functions of the D2R, we 
have mated the D2Rfloxflox mice with a mouse carrying the Cre 
recombinase under the control of the engrailed-1 (En1) gene promoter 
(Kimmel et al. 2000). 
The expression of the engrailed-1 (EN1) gene is restricted to the major 
mesencephalic dopaminergic nuclei, the SNc and VTA. The En-1 gene 
is a homeobox gene which is important during embryo development, 
indeed animals lacking this gene are not viable and do not have a 
cerebellum in a CD1 mouse background. En-1 is also expressed in the 
adult although its role at this stage has not been completely 
elucidated(Gherbassi and Simon 2006). Therefore, mice obtained from 
the mating of D2Rfloxflox mice with En-1CRE mice should not express 
D2R in the SNc and VTA. Thus, we performed in situ hybridization 
analyses comparing D2Rfloxflox mice and D2Rfloxflox/En1CRE/+ mice (Fig  6). 
Thus, we prepared an antisense 35S-labeled riboprobe of exon2 of the 
D2R gene and hybridized this probe to brain cryosections (10 µm) of 
both D2Rfloxflox and D2Rfloxflox/En1CRE/+ mice. These analyses showed the 
specific deletion of the D2R in the SNc and VTA in D2Rfloxflox/En1CRE/+ 
compared to WT controls; the expression of the D2R mRNA is instead 
normal in the Caudate putamen (CPu) and Nucleus accumbens (NAcc) 
of both genotypes (Fig. 6a). 
To support these experiments at the protein levels, ligand binding 
analyses were performed on striatal membranes using 3H-spiperone, a 
D2-like specific antagonist. This experiment showed 20 % reduction of 
D2R binding sites in D2Rfloxflox/En1CRE/+ compared to control, imputable to 
the deletion of D2R from the VTA and SNc dopaminergic projections. 
However, no difference in the receptor affinity for the ligand were 
observed(Fig. 6b). In addition, we also controlled whether D2R ablation 
might induce differential expression of D1R or a change in the affinity 
for D1 ligands, but no differences either in the number of D1 receptors 
sites or affinity for 3H-SCH 23390 were detected (Fig 6c).Together 
these analyses showed the specific ablation of presynaptic D2 
autoreceptor from the dopaminergic neurons, making them a suitable 
model to study the role of presynaptic D2 autoreceptors in vivo. 
 
 
 
 
 
 
 
  
27 
 
 
 
Fig.6) Characterization of the D2Rfloxflox/En1Cre/+ mice. 
 a)In situ hybridization using the D2R Exon2 probe showing selective 
ablation of D2R in SN and VTA () for the D2Rfloxflox/En1Cre/+ no 
difference in the CPu and Nacc between the genotype . b) D2R binding 
sites on striatal membranes from D2Rfloxflox (■) (Bmax = 884 ± 25 
fmol/mg protein; Kd = 171 ± 49 pM) and D2Rfloxflox/En1Cre/+ (□) (Bmax = 
690 ± 37 fmol/mg protein; Kd = 132 ± 21 pM).c) Pharmacological 
characteristics of D1R binding sites in D2Rfloxflox and D2Rfloxflox/En1Cre/+ 
striatal membranes. (■) (Bmax = 1703 ± 204 fmol/mg protein; Kd = 297 
± 93 pM) and D2Rfloxflox/En1Cre/+ (□) (Bmax = 1682 ± 168 fmol/mg protein; 
Kd = 354 ± 115 pM). Values are given ± S.E.M. (n=3). 
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Postsynaptic D2 heteroreceptor mutant 
   D1R and D2R are highly expressed in the MSNs of 
the striatum. To generate a mouse in which the expression of the D2R 
is ablated in MSNs we have mated our D2Rfloxflox mice with a mouse in 
which the Cre recombinase is expressed under the control of D1R 
receptor (D1-CRE mice) (Lemberger et al. 2007). Mice so generated, 
named D2Rfloxflox/D1CRE/+, should not express any longer the D2R in 
these neurons. To test the site-specific ablation of D2R in MSNs, in situ 
hybridization analyses were performed by comparing D2Rfloxflox mice 
and D2Rfloxflox/D1CRE/+ mice. 
Experiments of in situ hybridization were performed as previously 
described for the presynaptic D2 autoreceptor mutants, using a 
antisense 35S-labeled riboprobe of exon 2 of the D2R gene. These 
analyses clearly showed the deletion of the D2R mRNA in CPu and 
NAcc of these mice (Fig.7a). However, D2R are also expressed in 
striatal cholinergic interneurons. To control that D2R mRNA was still 
expressed in these cells, we performed double in situ experiments 
using an antisense digoxigenin (DIG)-labeled riboprobe for the choline 
acetyltransferase (ChAT) cDNA together with the exon 2 riboprobe. The 
results of these analyses showed that D2R mRNA was specifically 
ablated only in the MSNs, while was still expressed in the cholinergic 
interneurons (Fig 8) in D2Rfloxflox/D1CRE/+ mice.  
To support these experiments at the protein level, ligand binding 
analyses were performed on striatal membranes using 3H-spiperone, as 
described in the presynaptic D2 autoreceptor mutant mice. These 
experiments confirmed a 70% reduction of D2R binding sites in 
D2Rfloxflox/D1CRE/+ mice as compared to D2Rfloxflox, with no changes in the 
affinity of the remaining receptors for the ligand (Fig 7b).Similar to the 
presynaptic D2 autoreceptor mutants, D2R deletion in MSNs does not 
result in differences in the number of sites or in the affinity of the D1R 
(Fig7c). Altogether these analyses confirm the suitability of the 
D2Rfloxflox/D1CRE/+ mice as a model to study the role of D2R on MSNs. 
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Fig.7) Characterization of the D2Rfloxflox/D1Cre/+ mice. 
 
a) In situ hybridization using the D2R Exon2 probe showing selective 
ablation of D2R in the CPu and NAcc for the D2Rfloxflox/D1Cre/+ mice. b) 
D2R binding sites on striatal membranes from D2Rfloxflox (■) (Bmax = 
875 ± 28 fmol/mg protein; Kd=184±52 pM) and D2Rfloxflox/D1Cre/+ (□) 
(Bmax=259 ± 35 fmol/mg protein; Kd= 198 ± 58 pM).c) Pharmacological 
characteristics of D1R binding sites in D2Rfloxflox (black bar) and 
D2Rfloxflox/D1Cre/+ (white bar) striatal membranes. (■) (Bmax = 1695 ± 269 
fmol/mg protein; Kd = 278 ± 85 pM) and D2Rfloxflox/D1Cre/+ (□) (Bmax = 
1686 ± 198 fmol/mg protein; Kd = 354 ± 104 pM). Values are given ± 
S.E.M. (n=3). 
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Fig.8) D2Rfloxflox and D2Rfloxflox/D1Cre/+ striatal characterization. 
 
Double in situ hybridizations of sections from D2Rfloxflox and 
D2Rfloxflox/D1Cre/+ mice using a 35S-labeled D2R-specific exon 2 probe 
together with the digoxigenin (DIG)-labeled choline acetyl transferase 
(ChAT) or glutamic acid decarboxylase 1 (Gad1) probes. b) D2Rfloxflox 
and c) D2Rfloxflox/D1Cre/+ sections in which the D2R and ChAT probes 
were used. These analyses showed persistence of D2R in striatal ChAT 
interneurons; arrows indicate ChAT labelled cells.  d) Double in situ 
hybridization using D2R and Gad1 probes in D2Rfloxflox; e) 
D2Rfloxflox/D1Cre/+ striatal sections; these analyses showed absence of 
D2R in MSNs. 
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D2R and motor activity  
 
Presynaptic D2 autoreceptor mutants. 
 
   One of the prominent functions of D2R is the control 
of motor activity (Baik et al.1995). 
To asses if the ablation of the D2R in the SNc and VTA neurons leads 
to impairments of motor functions in the presynaptic D2 autoreceptor 
mutants (D2Rfloxflox/En1CRE/+), these animals and their control littermates 
(D2Rfloxflox) were tested for their locomotion in a new home cage and in 
their performance on the rotarod test (Baik et al. 1995; Usiello et al. 
2000) to assess their motor coordination. Interestingly, the results of 
these analyses (Fig. 9a and 10a) show no difference in the motor 
behavior of these mice as compared to control mice either in the new 
home cage or on the rotarod.  
Then, we tested D2Rfloxflox/En1CRE/+ and D2Rfloxflox mice in the open field 
(Fig.9b). The open field is a behavioral paradigm that contains an 
anxiogenic component and measures the reactivity of the subject to the 
novel, mildly stressful environment and how the subject reacts to it by 
measuring the time to habituate to it. This test allows to have a 
qualitative and quantitative measures of the animal locomotor’s activity; 
in addition behavior in this test has been shown to depend on 
responses mediated by the mesolimbic system (Hooks and Kalivas 
1995) in contrast to those obtained in the home cage that are 
dependent on the activation of nigrostriatal system(Hooks and Kalivas 
1995). Importantly, when D2Rfloxflox/En1CRE/+ mice were tested in the open 
field, they showed an exaggerated response both in horizontal and 
vertical movements, as compared to controls. Similarly, when motor 
activity was challenged in response to an acute administration of 
cocaine (DAT blocker), which also engages responses of the 
mesolimbic system (Delfs et al. 1990) , we also observed an 
outstanding increase of the motor activity in D2Rfloxflox/En1CRE/+ as 
compared to WT siblings (Fig.9c). Altogether, these results indicate that 
loss of presynaptic D2 autoreceptors results into an over-response to a 
novel environment and increased sensitivity to cocaine, both 
parameters connectable to an altered presynaptic D2 autoreceptor 
mediated control of DA. They also suggest that D2 autoreceptor 
deficiency is more evident in functions dependent from the mesolimbic 
than the nigrostriatal system. 
 
Postsynaptic D2 heteroreceptor mutants 
 
    To analyze the role of the D2R expressed in the 
MSNs on motor activity, we performed the behavioral tests described in 
the above paragraph, on D2Rfloxflox/D1CRE/+ and compared to that of 
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D2Rfloxflox mice. Importantly, the motor phenotype of D2Rfloxflox/D1CRE/+ 
mice strongly resembles that of D2R-null mice previously analyzed in 
the laboratory (Baik et al. 1995). Indeed, D2Rfloxflox/D1CRE/+ mice are 
characterized by a strong impairment of horizontal and vertical activity 
and fail to perform on the rotarod (Fig 9d and 10b). The motor 
impairment is as outstanding when postsynaptic D2 heteroreceptor 
mutants were tested in the open field (Fig 9e). In addition, and again in 
line with results obtained in D2R-null mutants, D2Rfloxflox/D1CRE/+ mice 
have a totally blunted response to cocaine (Fig. 9f) (Welter et al. 2007). 
Altogether these results show that the presence of D2R on striatal 
MSNs is an absolute requirement to translate inputs into motor activity. 
 
 
Fig.9) Loss of D2 autoreceptors or heteroreceptors differently 
affects motor behavior. 
 a) Locomotion and rearing activity of D2Rfloxflox (black bars) and 
D2Rfloxflox/En1Cre/+ (white bars) mice in the home cage (n = 9-10). No 
difference was observed between genotypes; Student’s t-test: P>0.05. 
b) Locomotion and rearing activity in the open field of D2Rfloxflox (black 
bars) and D2Rfloxflox/En1Cre/+ (white bars) (n = 9-10); Student’s t-test: * P < 
0.05 and rearing ** P<0.01.c) Motor activity after acute cocaine injection 
(15mg/kg) recorded for 30 min. D2Rfloxflox (black bars) and 
D2Rfloxflox/En1Cre/+ (white bars). Two-way Anova Treatment x Genotype, 
(F(1,34) = 5.249), P<0.05. Saline vs treated *: P<0.05, **: P<0.01. 
D2Rfloxflox/En1Cre/+ vs D2Rfloxflox #: P<0.05. d) Locomotion and rearing 
activity of D2Rfloxflox (black bars) and D2Rfloxflox/D1Cre/+ (white bars) mice in 
the home cage (n = 9-10). Student’s t-test: *** P < 0.001; e) Locomotion 
and rearing activity in the open field of D2Rfloxflox (black bars) and 
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D2Rfloxflox/D1Cre/+ (white bars) (n = 9-10). Student’s t-test: ** P<0.01 *** 
P<0.001. f) Motor activity after acute cocaine injection (15mg/kg) 
recorded for 30 min. D2Rfloxflox (black bars) and D2Rfloxflox/D1Cre/+ (white 
bars). Two-way Anova Treatment x Genotype, (F(1,49)=5.759),  P<0.05. 
Saline vs treated *: P<0.05, D2Rfloxflox/D1Cre/+ vs  D2Rfloxflox #:P<0.05 , ###: 
P<0.001 
 
 
 
Fig.10) Motor coordination was assessed using the rotarod test.  
 a) Values represent the average ± S.E.M. of time (sec) spent on the 
rotarod across four days by D2Rfloxflox (■) and D2Rfloxflox/En1Cre/+ (□) mice. 
Both genotypes showed similar latency to fall (F (3,36) = 1.178, P > 0.05) 
and improved their performance with time (F(3,36) = 14.426, P <0.001). 
The rotarod test was performed by placing mice on the rotating rod and 
measuring their fall latencies. Rotations were increased from 4 to 40 
rpm over a period of 5 min. Mice were given 3 trials/day on 4 
consecutive days; in each day the best performance was used for 
analysis. Rotarod data were analyzed by ANOVA with repeated 
measures. b) same as in a) for D2Rfloxflox (■) and D2Rfloxflox/D1Cre/+ (□) 
mice. D2Rfloxflox/D1Cre/+ showed shorter latencies to fall (F (3,34) = 6.239 
P<0.05).  Values represent the average ± S.E.M. of time (sec) spent on 
the rotarod across four days. 
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Behavioral responses of pre- and post-synaptic D2r mutants to 
pharmacological challenge of D2-like agonists and antagonists. 
Presynaptic D2 autoreceptor mutant mice.  
 
D2-like agonist administration. 
 
   Presynaptic D2 autoreceptor mutants were then 
analyzed for their behavioral response to pharmacological challenge 
using dopaminergic D2-like specific ligands. For this, D2Rfloxflox/En1CRE/+ 
and D2Rfloxflox mice were treated with quinpirole, a D2-like specific 
agonist known to induce motor sedation at low doses by activation of 
D2 autoreceptor (Usiello et al. 2000). Mice of both genotypes were thus 
treated either with saline or quinpirole at the doses of 0.02 mg/kg and 
0.2 mg/kg and then tested for their locomotor activity in a new home 
cage. The D2Rfloxflox/En1CRE/+ mice at the dose of 0.02mg/kg did not 
present any reduction in the locomotor activity compared to the saline 
treated, while WT mice, as expected showed a reduction of locomotion 
(Fig.11a). Strikingly, however at the dose of 0.2 mg/kg of quinpirole, we 
observed a reduction of motor activity in D2Rfloxflox/En1CRE/+ mice as 
compared to the saline treated, similar to that observed in WT controls 
although less potent (Fig 11a). These results contrast with the expected 
loss of effect of low doses of quinpirole in the absence of D2 
autoreceptors and suggest the involvement of postsynaptic D2R in the 
motor sedative effect of quinpirole. Importantly, when the same 
experiments was performed with mice of both genotype exposed to the 
open field, while the WT equally showed a reduction of motor activity, 
the D2Rfloxflox/En1CRE/+ mice at 0.2 mg/kg did not show any reduction of 
motor activity compared to the saline treated of the same genotype 
(Fig. 12). Thus, in the absence of D2 autoreceptors quinpirole elicits an 
effect in the new home cage, but not in the open field suggesting that 
quinpirole affects responses mediated by the nigrostriatal pathway 
through projections from the SNc to the striatum more than the 
mesolimbic pathway. These results are in agreement with those 
obtained in the absence of any pharmacological challenge in the open 
field versus the home cage, again showing a differential effect of loss of 
D2 autoreceptors in projections to the NAcc versus the dorsal striatum.   
 
Postsynaptic D2 heteroreceptor mutants.  
 
D2-like agonist administration 
 
   As for the D2Rfloxflox/En1CRE/+ mice, D2Rfloxflox/D1CRE/+ 
mice have been tested for their locomotor activity under quinpirole 
pharmacological challenge. 
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D2Rfloxflox/D1CRE/+ mice did not shown a decrease in the locomotor activity 
when administered with 0.02 mg/kg of quinpirole as compared to saline 
treated mice; while they showed a decrease at 0.2 mg/kg (Fig. 11d). 
We believe that the absence of effect of quinpirole at the dose of 
0.02mg/kg is dependent on the already strong impairment of motor 
activity in D2Rfloxflox/D1CRE/+ mice as compared to WT littermates. Indeed, 
at the dose of 0.2mg/kg they showed a reduction as compared to the 
saline treated of the same genotype. These experiments show that 
quinpirole still preserves the property to reduce movements in mice 
lacking D2R in MSNs, through activation of D2 autoreceptors still 
present in the SNc and VTA of D2Rfloxflox/D1CRE/+ mice. 
 
 
Presynaptic D2 autoreceptor mutants; 
 
 D2-like antagonist administration. 
 
   Haloperidol is a specific D2-like antagonist. This 
drug is able to induce catalepsy when it is administered systemically 
through blockade of D2 heteroreceptor located at postsynaptic sites. 
D2Rfloxflox/En1CRE/+ mice and the WT siblings were thus challanged with 
either saline or 0.04 ,0.4 and 4 mg/kg of haloperidol, and the catalepsy 
has been measured by performing the bar test (Fig.11b). Three hours 
after treatment, mice were positioned with the front paws on a metallic 
bar situated at 3.5 cm from the floor and the time needed for bringing 
the paws to the floor scored. D2Rfloxflox/En1CRE/+ mice showed a stronger 
degree of catalepsy at the lower doses (0.04mg/kg) of haloperidol as 
compared to WT controls. While at the dose of 0.4 and 4 mg/kg 
haloperidol no differences in catalepsy were observed between 
D2Rfloxflox/En1CRE/+ mice and WT controls. These results show that in 
D2Rfloxflox/En1CRE/+ mice the postsynaptic D2 heteroreceptor mediated 
signaling is preserved. The higher response of D2Rfloxflox/En1CRE/+ mice to 
the lower dose of haloperidol (0.04mg/kg)  can be explained by the 
reduced number of binding sites present in these mice (as showed in 
the binding experiment), which very likely allow an increase of the 
available drug in these mutants. 
 
Postsynaptic D2 heteroreceptor mutants; D2-like antagonist  
administration 
 
   D2Rfloxflox/D1CRE/+ mice were tested for the effect of 
haloperidol on catalepsy by the bar test as previously described in 
D2Rfloxflox/En1CRE/+ mice. In these mice, we used the two highest 
concentrations of haloperidol (0.4 mg/kg and 4 mg/kg) (Fig. 11d). 
Interestingly, in D2Rfloxflox/D1CRE/+ mice we did not observe catalepsy at 
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the dose of 0.4 mg/kg as compared to WT controls; a minimal effect 
was observed at 4mg/kg which was anyway irrelevant respect to that 
obtained in WT controls. These data support the role of D2Rs 
expressed by the MSNs in eliciting the cataleptic effects of haloperidol 
 
 
Fig.11)  Behavioral effects of D2-like agonists and antagonists in 
D2Rfloxflox/En1Cre/+ and D2Rfloxflox/D1Cre/+ mice. 
a) Differential quinpirole induced motor sedation in D2Rfloxflox (black 
bars) vs D2Rfloxflox/En1Cre/+ (white bars) mice; Two-way Anova significant 
Genotype (F(1,48) = 18.967, P < 0.001) and Treatment effects (F(2,48) = 
17.878, P < 0.001).  b) Haloperidol-induced catalepsy in D2Rfloxflox 
(black bars) and D2Rfloxflox/En1Cre/+ (white bars) mice; Two-way Anova 
Treatment effect (F(3,81) = 135.637, P <0.001) and a trend toward 
genotype effect (F(1,81) = 3.906, P = 0.052). c) Quinpirole induced 
sedation in D2Rfloxflox (black bars) vs D2Rfloxflox/D1Cre/+ (white bars) mice; 
Two-way Anova: Genotype x Treatment (F(2,37)= 8.284 p<0.01. d) 
Haloperidol-induced catalepsy in D2Rfloxflox (black bars) vs 
D2Rfloxflox/D1Cre/+ (white bars) mice. Two-way Anova Genotype x 
Treatment effect (F(2,57)  =14.635 p<0.001) Saline vs treated *: P<0.05; 
**: P<0.01;*** :  P <0.001; D2Rfloxflox/En1Cre/+ treated vs D2Rfloxflox treated 
#: P<0.05; ##: P < 0.01. D2Rfloxflox/D1Cre/+ treated vs D2Rfloxflox treated 
+++: P< 0.001. 
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Fig.12) Open field in D2Rfloxflox/En1cre/+ 
D2Rfloxflox (black bars) and D2Rfloxflox/En1Cre/+ (white bars) were treated 
with quinpirole (0.2mg/kg) and immediately exposed to the open field 
for 30 min. Motor activity was measured with a videotracking system. 
While quinpirole induced motor sedation in D2Rfloxflox mice, no effect of 
this drug was observed in D2Rfloxflox/En1Cre/+ mice. Treatment x Genotype, 
(F(1,33)=10.94). Saline vs quinpirole ***: P < 0.001; D2R
floxflox treated vs 
D2Rfloxflox/En1Cre/+ treated   ##: P < 0.01. 
 
Pre- and post-synaptic D2R-mediated effects on DA synthesis and 
release 
Electrophysiological characterization of the response of 
dopaminergic neurons in D2Rfloxflox/En1CRE/+ mice.  
 
   To assess the firing properties of dopaminergic 
neurons in D2Rfloxflox/En1CRE/+ mice, we collaborated with the laboratory of 
Dr. Antonello Bonci. Ex-vivo brain slice electrophysiology was 
performed. Recordings were performed in cell-attached mode to 
preserve the natural intracellular milieu of the neurons. SNc and VTA 
neurons from D2Rfloxflox/En1CRE/+ mice and control littermates were tested. 
SNc and VTA neurons possessed action potential waveforms of ~1.5-
1.8 ms under the cell-attached configuration (Ungless et al. 2004 ), and 
were Ih (hyperpolarization-activated current) positive when examined 
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after breaking into whole-cell mode at the end of the experiment. D2R 
receptors negatively regulate firing in midbrain DA neurons by activating 
hyperpolarizing inward rectifier K+ (GIRK) channels (Beckstead et al. 
2004). Neurons from WT mice showed the expected suppression of 
firing by quinpirole (2 µM) in both SNc and VTA; while neurons from 
D2Rfloxflox/En1CRE/+ mice did not show this inhibition. The GABAB receptor 
agonist baclofen (2 µM) was able to strongly inhibit firing in both WT 
and D2Rfloxflox/En1CRE/+ neurons, suggesting that activation of GIRK 
channels by a receptor other than D2R remained intact in neurons 
lacking presynaptic D2 autoreceptors (Fig. 13). 
 
 
 
Fig. 13) Electrophysiological characterization of SNc and VTA 
neurons of D2Rfloxflox/En1Cre/+ mice. 
a) Loss of presynaptic D2 autoreceptor-mediated inhibition of firing in 
SNc and VTA of D2Rfloxflox/En1Cre/+ mice as compared to control mice. b) 
Normal GABAB-mediated inhibition of firing in both genotypes 
(representative examples). 
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Tissue content of DA and its metabolites in D2Rfloxflox/En1CRE/+ mice. 
 
    The tissue content of DA and its metabolites 3,4-
dihydroxyphenylacetic acid (Dopac) and homovanilic acid (HVA) was 
determined in homogenates of tissues punches from the Nucleus 
accumbens  and  dorsal striatum of D2R presynaptic ko mice and their 
control littermates. 
The content was quantified by high performance liquid chromatography 
(HPLC) analysis. The total content of DA and HVA was increased in the 
NAcc and cortical extracts of D2Rfloxflox/En1CRE/+ mice as compared to the 
WT littermates. Importantly, no differences either in DA or in its 
metabolites were observed in extracts from the dorsal striatum between 
D2Rfloxflox/En1CRE/+ mice and WT controls (Fig.14 a,b,c). 
 
Tissue content of DA and metabolites in D2Rfloxflox/D1CRE/+ mice. 
 
   The content of DA and its metabolites was similarly 
analyzed D2Rfloxflox/D1CRE/+ mice and WT littermates. In this case, no 
differences were observed between genotypes in all the regions tested 
(Fig.14 c,d,e). 
 
 
 
Fig.14) Percentage of DA, DOPAC and HVA in D2Rfloxflox/En1Cre/+ and, 
D2Rfloxflox/D1Cre/+ . 
D2Rfloxflox levels, were arbitrarily set at 100%. Determination were made 
by HPLC on extracts from tissue punches of a) DSt; b) NAcc and c) 
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PFC from D2Rfloxflox (black bars), D2Rfloxflox/En1Cre/+ (white bars).  d) DSt; 
e) NAcc and f) PFC from D2Rfloxflox (black bars), D2Rfloxflox/D1Cre/+ (white 
bars).*P<0.05,**P<0.01.Student’s was used for statistical analysis. 
 
 
DA release  
 
DA release in D2Rfloxflox/En1CRE/+ mice. 
 
   To assess the role of D2 autoreceptors on the DA 
release from neuronal terminals, we performed in D2Rfloxflox/En1CRE/+ mice 
(collaboration with Dr. David Sulzer’s laboratory) cyclic voltammetry 
experiments in acute brain slices of dorsal striatum and NAcc, under 
normal conditions or in the presence of quinpirole (D2-like agonist). 
In the dorsal striatum, D2Rfloxflox/En1CRE/+ mice compared to the WT mice 
showed a reduction in DA overflow close to 70% when they were 
challenged by a single pulse. However, when the same area was 
challenged with a train of 5 or 10 pulses at 20 Hz, D2Rfloxflox/En1CRE/+ 
mice showed an increase of DA overflow of 1.1 and 1.2 fold, 
respectively as compared to the control mice (Fig.15). 
D2Rfloxflox/En1CRE/+ mice and WT littermates were then tested for DA 
release in the presence of quinpirole. In these conditions, unexpectedly, 
D2Rfloxflox/En1CRE/+ mice showed a reduction of DA release of around 80% 
as compared to the WT controls (Fig.15b) 
Then we performed the similar analyses in the NAcc of 
D2Rfloxflox/En1CRE/+ mice and WT littermates by cyclic voltammetry. In this 
case we could only perform experiments in the absence of quinpirole 
due to the low baseline DA level in this area, which makes the amount 
of DA detectable close to background levels. 
D2Rfloxflox/En1CRE/+ mice compared to WT controls showed a decrease of 
DA overflow close to 41% by the single pulse in cyclic voltammetry. The 
20 Hz train of pulse at 5 and 10 showed an increase in the DA release 
of 1.3 and 1.4 fold respectively, as compared to the WT controls 
(Fig.16) 
The results obtained by single pulses in D2Rfloxflox/En1CRE/+ mice are 
similar to those previously described in the D2R-null mouse model 
(Schmitz et al. 2002). The effect of quinpirole was however completely 
unexpected, since this drug continued to inhibit DA overflow in the 
absence of D2 autoreceptors in marked contrast with the complete loss 
of quinpirole inhibition in D2R-null mice (Benoit-Marand et al. 
2001;Schmitz et al. 2002). These results contradict the “assumption” 
that the inhibition of DA release by quinpirole is selectively due to the 
activity of presynaptic D2 autoreceptors and strongly point to a 
postsynaptic D2R-mediated intervention of D2 heteroreceptors in the 
control of DA release in the absence of autoreceptors.  
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FIG.15) DA release in the dorsal striatum of D2Rfloxflox/En1Cre/+ 
 
a) Single-pulse stimulation in D2Rfloxflox/En1Cre/+ mice (n = 1920) b) 
D2Rfloxflox/En1Cre/+ mice DA overflow in the presence of quinpirole.  (50 
nM: n = 7, F(1,261) = 8.46, P = 0.0039; 500 nM: n = 78, F(1,204) = 23.52, 
P < 0.001).c) Train of pulses at 20 Hz displayed enhanced DA overflow 
in D2Rfloxflox/En1Cre/+ mice (CV; n = 612; genotype: F(1,32) = 18.98, P = 
0.0001). 
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Fig.16) Voltammetry NAcc of D2Rfloxflox/En1Cre/+ 
 
a) Cyclic voltammetry experiments in the shell of the NAcc of 
D2Rfloxflox/En1Cre/+ mice. b) Train of pulses at 20 Hz displayed enhanced 
DA overflow in the shell of the NAcc of D2Rfloxflox/En1Cre/+ (n = 69; F(1,29) 
= 21.37, P < 0.0001). 
 
 
 
DA release, in D2Rfloxflox/D1CRE/+ mice. 
 
   Cyclic voltammetry in presence and absence of 
quinpirole was also performed in the dorsal striatum of D2Rfloxflox/D1CRE/+ 
mice and WT littermates. 
Importantly, when the D2Rfloxflox/D1CRE/+ mice were tested by a single 
pulse, they showed a slight decrease of DA overflow of around 20% in 
comparison to WT littermates. In the train of 5 or 10 pulses at 20 Hz no 
difference in DA release were noted with respect to WT controls 
(Fig.17). When D2Rfloxflox/D1CRE/+ mice were analyzed in the presence of 
quinpirole, interestingly they showed an inhibition of DA overflow, which 
did not reach the level of WT (79%). 
These data strongly support a role of the postsynaptic D2 
heteroreceptors in the regulation of DA release from the presynaptic 
dopaminergic terminals. Thus, for the first time, we were able to show 
that DA release is not only controlled by autoreceptors, but that in their 
absence an inhibitory feedback is established which is activated by 
postsynaptic D2R. 
 
 
  
43 
 
 
Fig.17) DA release in the dorsal striatum of D2Rfloxflox/D1Cre/+ 
 a) Single-pulse stimulation in D2Rfloxflox/D1Cre/+ mice (n = 3537). b) 
D2Rfloxflox/D1Cre/+ mice Da overflow in the presence of quinpirole (500 nM 
(n = 910, F(1,274) = 33.23, P < 0.0001).c) Train of pulses at 20 Hz 
displayed no changes in DA overflow in D2Rfloxflox/D1Cre/+ mice (CV; n = 
812; genotype: F(1,36) = 2.76, P = 0.11). 
 
DA reuptake 
   DA reuptake can be estimated with CV from the 
kinetic parameters of falling phase of the signal: of these, the duration 
at half-height is a particularly reliable indicator of reuptake .We noted a 
significant increase in DA reuptake in D2Rfloxflox/En1CRE/+ mice, whereas 
reuptake by D2Rfloxflox/D1CRE/+ mice was identical to WT littermates 
(Fig.18). In addition, we observed that while the DAT inhibitor, 
nomifensine (5 M), did not increase the amplitude of evoked DA 
overflow of  D2Rfloxflox/En1CRE/+ mice to levels of the WT (0.92 vs 2.36 M, 
respectively; Fig.18c) the normalized increase of peak amplitude was 
higher in the mutant (2.8 vs 2.0-fold increase, respectively; Fig.18d). 
This enhanced response to nomifensine is consistent with a greater 
relative contribution of DAT activity to peak amplitude in the presynaptic 
D2 autoreceptor mutant, and is consistent with D2 autoreceptor 
inhibition of reuptake.  Only the D2 autoreceptor, however, appears to 
inhibit reuptake by DAT even if the postsynaptic D2R showed an effect 
when the system is challenged with quinpirole. 
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Fig.18) DA reuptake 
D2Rfloxflox: (black bars), D2Rfloxflox/En1Cre/+ or D2Rfloxflox/D1Cre/+: (white bars). 
a) Decay parameters calculated from the DA overflow spikes obtained 
from CV experiments showing that D2Rfloxflox/En1Cre/+ mice exhibit a 
significant change in spike width (t1/2). The decay time from the 75 to 
25% of the spike (fall time) and the decay constant () presented no 
changes (n = 1617). b) Decay parameters calculated from the DA 
overflow spikes in D2Rfloxflox/D1Cre/+ mice showed no significant changes 
in spike width, decay time, and decay constant (CV: n = 1314; AMP: n 
= 10). c) DA overflow measured in D2Rfloxflox/En1Cre/+ mice during 
nomifensine-mediated blockade of DAT does not reach the same levels 
of WT mice (nomifensine: 5 M; n = 4; increase in [DA], D2Rfloxflox: 2.36 
M; D2Rfloxflox/En1Cre/+: 0.92). d) Nomifensine-mediated blockade of DAT 
induces a significant increase in DA overflow in D2Rfloxflox/En1Cre/+ mice 
when compared to the baseline-normalized response with respect to 
WT mice (nomifensine: 5 M; n = 4; increase in [DA], D2Rfloxflox: ~2-fold; 
D2Rfloxflox/En1Cre/+: ~2.7-fold; F(1,89) = 8.61, P = 0.004). Maximal DA-
overflow concentration and normalized response were calculated using 
a nonlinear regression which takes in consideration the plateau and the 
rising independently. Two-tailed unpaired t-test with Welch’s correction 
was used in panel a) and b). 
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DA synthesis 
 
DA synthesis in D2R presynaptic ko 
  
 
   In addition to modulate DA release, D2 receptor has 
also the important function to inhibit DA synthesis. 
Tyrosine hydroxylase (TH) is the rate limiting enzyme of DA synthesis; 
its activity is increased by phosphorylation at Ser 40 (Lindgren et al. 
2000). To assess the role of pre- and post-synaptic D2R on TH activity 
we prepared protein extracts from tissue punches of dorsal striatum and 
NAcc and analyze them by western blot using specific antibodies raised 
against TH phosphorylated at Ser 40. Quantifications of the bands 
obtained this way were then expressed as ratio over total TH, to control 
for the amount of protein present in the extracts. It is important to point 
out that all extracts showed an equal amount of total TH, indicating that 
TH expression is not altered between mutants and control mice. 
Interestingly, we found that absence of D2 autoreceptors in 
D2Rfloxflox/En1CRE/+ mice does not alter the TH phosphorylation level on 
Ser 40 in the striatum as compared to WT controls. However, in the 
NAcc we found an important increase of this TH modification as 
compared to WT extracts. These data are in agreement with those 
obtained by the HPLC analyses. D2Rfloxflox/En1CRE/+ mice and controls 
were then administered with quinpirole at the concentration of 0.2 
mg/kg and TH phosphorylation was analyzed. Interestingly, while in the 
dorsal striatum of both genotypes, quinpirole was still able to reduce TH 
phoshorylation at Ser 40; it did not affect this parameter in the NAcc of 
D2Rfloxflox/En1CRE/+ mice (Fig.19). 
These results indicate the presence of a postsynaptic D2R activated 
feedback mechanism in the striatum that control TH activity; this 
mechanism becomes evident in the absence of D2 autoreceptors. 
In the NAcc this mechanism seems to not be present, in agreement with 
the hyper-activity showed by D2Rfloxflox/En1CRE/+ mice when tested in a 
novel environment (open field) or when administered with cocaine; both 
conditions activating the VTA-NAcc pathway. 
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Fig.19) pTH-Ser40 levels in DSt and NAcc extracts of 
D2Rfloxflox/En1Cre/+. 
Western-blot analyses of pTH-Ser40 levels in DSt and NAcc extracts (30 
µg/sample) of D2Rfloxflox/En1Cre/+, D2Rfloxflox/D1Cre/+ and D2Rfloxflox mice 
treated either with saline or with quinpirole (0.2mg/kg), as indicated. 
Values represent the ratio of pTH-Ser40 /total TH; the values of the ratio 
from saline treated D2Rfloxflox mice were arbitrarily set at 100%. a) 
Ratios obtained from the analyses of DSt extracts from D2Rfloxflox (black 
bars) and D2Rfloxflox/En1Cre/+ (white bars). Two-way Anova shows no 
genotype effect: F(1,17)=1.848 p>0.05). b) Same as in a) for NAcc 
extracts, D2Rfloxflox (black bars) and D2Rfloxflox/En1Cre/+ (white bars). Two-
way Anova shows  Genotype effect: F(1,17)=33.126 P<0.001. Values are 
mean ± s.e.m. *: P < 0.05, **: P < 0.01, ***: P < 0.001 vs saline control. 
D2Rfloxflox vs D2Rfloxflox/En1Cre/+ #: P < 0.05,  ##: P < 0.01. 
 
DA synthesis in the postsynaptic ko mice. 
TH phosphorylation at Ser 40 was then analyzed in D2Rfloxflox/D1CRE/+ 
mice using the same approach used for the analysis of D2Rfloxflox/En1CRE/+ 
mice. Extracts from dorsal striatum and NAcc of D2Rfloxflox/D1CRE/+ mice 
and WT littermates were analyzed by western blot analysis. Under 
saline conditions, D2Rfloxflox/D1CRE/+ mice did not differ from WT 
littermates in the amount of TH phosphorylation at Ser 40, both in the 
dorsal striatum and NAcc. Also, both genotypes equally showed a 
reduction of TH phosphorylation at the Ser40 residue when challenged 
with 0.2mg/kg of quinpirole (Fig.20). 
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These results clearly show the presence of D2 autoreceptors in 
D2Rfloxflox/D1CRE/+ mice is sufficient to ensure the appropriate control over 
DA synthesis, suggesting that the D2-mediated postsynaptic feedback 
on DA synthesis becomes evident only when the D2 autoreceptors are 
absent. 
 
 
 
 
 
Fig.20) pTH-Ser40 levels in DSt and NAcc extracts of D2Rfloxflox/D1Cre/+ 
 
D2Rfloxflox/D1Cre/+ (white bars) and D2Rfloxflox (Black bars) mice treated 
either with saline or with quinpirole (0.2mg/kg), as indicated. Values 
represent the ratio of pTH-Ser40 /total TH; the values of the ratio from 
saline treated D2Rfloxflox mice were arbitrarily set at 100%. a)  Ratios 
obtained from the analyses of DSt extracts from D2Rfloxflox (black bars) 
and D2Rfloxflox/D1Cre/+ (white bars) Two-way Anova no Genotype effect: 
F(1,18) =1.984 P > 0.05. b) Same analysis as in a) but using NAcc 
extracts from D2Rfloxflox (black bars) and D2Rfloxflox/D1Cre/+ (white bars). 
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Discussion 
 
DA is a key neurotransmitter in the basal ganglia. The understanding 
and the study of dopaminergic system is difficult due to the presence of 
dopaminergic receptors in different areas of the brain with similar 
pharmacological pattern. 
The study of the D2 receptor is made difficult due to the presynaptic 
and postsynaptic localization, this makes hard to discern the functions 
based on pharmacological treatment. 
During my thesis I have used mouse models previously generated in 
the laboratory; in these models the D2 receptor has been removed in a 
site-specific manner either from the dopaminergic neurons or in striatal 
MSNs. 
DA functions are implicated in a broad range of neurological, 
neuropsychiatric and endocrine disorders (Grace et al. 2008). The 
analysis of D2R-null mice has been critical to assess the importance of 
this receptor in dopaminergic functions (Baik et al. 1995). However the 
full ablation of D2R from every site expressing it did not allow the 
analysis of the presynaptic (autoreceptor) versus the postsynaptic 
(heteroreceptor) mediated functions in vivo. 
Interestingly, the comparison of pre- and post-synaptic D2R mutants 
has shown unexpected results. Indeed, D2Rfloxflox/En1CRE/+ mice show 
normal motor activity and coordination with respect to D2Rfloxflox/D1CRE/+ 
mice, in which the motor activity is highly depressed. Thus, loss of D2 
autoreceptors does not seem to have a strong impact on locomotion 
under basal conditions; instead, these animals are hyperactive when 
exposed to a novel environment and they show an increased motor 
response when administered with cocaine (DAT blocker). On the 
contrary, the analysis of D2Rfloxflox/D1CRE/+ mice shows the importance of 
postsynaptic D2 receptor on MSNs for a normal locomotion; the 
absence of D2 receptor in these neurons prevents a normal motor 
activity and coordination. In addition, D2Rfloxflox/D1CRE/+ mice show a 
minimal response to cocaine administration, which closely resemble the 
phenotype of D2R-null mice.  
Loss of D2 autoreceptors in D2Rfloxflox/En1CRE/+ mice results in the inability 
by D2 agonists to inhibit the firing properties of dopaminergic neurons. 
Cyclic Voltammetry analyses performed in pre-synaptic D2 autoreceptor 
mutants have shown a reduced DA overflow in single pulse 
experiments in the dorsal striatum, similar to that observed in D2R-null 
mice (Schmitz et al. 2002). However, the same experiment performed in 
the NAcc showed a less efficient reduction of DA overflow, these 
findings suggest a different control over DA release in the dorsal or 
ventral striatum with important physiological implications. In addition, we 
were able to show for the first time the presence of a postsynaptic D2R-
mediated feedback mechanism controlling DA release. This role has 
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been further demonstrated at the level of DA synthesis, by the ability of 
quinpirole to decrease TH phosphorylation at Ser 40 in the dorsal 
striatum of D2Rfloxflox/En1CRE/+ mice. This inhibition is very likely not due to 
the D2R-mediated inhibition of the cAMP levels, but dependent of the 
activation of postsynaptic circuits regulating the activity of dopaminergic 
neurons. This postsynaptic effect appears to have a minor role in the 
NAcc in which the single pulse voltammetry experiment showed a 
smallest reduction of DA overflow than in the striatum and in which TH 
phosphorylation is not inhibited by quinpirole.  
The differences between dorsal striatum and NAcc are further 
confirmed by behavioral analyses showing that the ability of quinpirole 
to reduce motor behavior was present only when D2Rfloxflox/En1CRE/+ mice 
were tested in the new home cage, while it did not affect the locomotion 
in the open field. The lowest amount of DA released from the NAcc, did 
not allow to measure the loss of inhibition in this region in the presence 
of quinpirole; nevertheless in the dorsal striatum of D2Rfloxflox/En1CRE/+ 
mice quinpirole is able to decrease DA release with less potency than in 
control mice mirroring the behavioral finding of the new home cage. 
In D2Rfloxflox/D1CRE/+ mice mice cyclic voltammetry showed that the 
inhibition by quinpirole of DA release is 20% less efficient than in the 
WT mice, despite to the presence of D2 autoreceptors on the 
dopaminergic neurons. This finding confirms behavioral analyses, in 
which despite of the presence of presynaptic D2 autoreceptors, 
quinpirole affected motor behavior only at the higher dose tested. 
D2Rs on dopaminergic neurons are key effectors in the control of DA 
release, nevertheless in their absence a postsynaptic D2R mediated 
feedback controls DA release. This control might be executed through 
regulation of circuits that converge onto dopaminergic neurons and 
could be mediated by other neurotransmitters such as glutamate, 
GABA, acethylcoline. 
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5. Conclusions 
 
   The findings of these studies bring us to propose 
that postsynaptic D2 heteroreceptors, in condition in which the 
autoreceptor is not functional, activate a feedback mechanism. This can 
be possible through increase/decrease of other neurotransmitters which 
could affect DA synthesis and release from the dopaminergic neurons 
(Bamford et al. 2004) (Surmeier et al. 2007). Importantly, the impact of 
absence of D2 autoreceptors on SNc and VTA neurons seems to be 
different. Synthesis is affected only in the projections to NAcc, but not in 
the projections to dorsal striatum in agreement with the DA tissue 
content and TH activity. The D2R-mediated feedback mechanisms 
controlling DA release, in the absence of D2 autoreceptors, seem to be 
confined to dorsal striatum. Dopaminergic neurons originating from VTA 
and SNc have been reported to have different properties (Lammel et al. 
2008) (Lammel et al. 2011) (Cragg 2005); these properties seems to be 
mediated not only from the different area of origin of dopaminergic 
neurons, but particularly from a D2R-mediated effect activated in 
postsynaptic neurons. 
Thus in conclusion, my studies show that DA synthesis and release are 
functions that can be assigned not only to the presynaptic D2 
autoreceptor, but also to postsynaptic D2 heteroreceptors. Indeed, 
when D2 autoreceptors are absent, DA stimulation of D2 
heteroreceptors reveals feedback mechanisms which become dominant 
in the control of dopaminergic neurons activity. 
Future studies might identify which other neurotransmitter could be 
responsible of these regulations and where these interactions take 
place. 
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